Company Overview and News

8
Sector ETFs & Stocks to Bet for Q3 Earnings

2018-10-15 zacks
After a tumultuous week, investors’ have turned their attention to earnings. The Q3 earnings season has kicked off, with a few major banks having reported last week. Earnings for the S&P 500 index are expected to grow 18.7% from the same period last year on 7.8% higher revenues. This would follow 25.5% earnings growth in Q2 on 9.8% revenue growth, the highest growth pace since 2010. Though the magnitude of earnings revision has moved down from 19.
PRU NOG PRH PHM PFK PRU ITB PJH

 
Winning ETF Strategies for the Fourth Quarter

2018-10-12 zacks
Volatility has roared back with the start of the fourth quarter as the CBOE Volatility Index (VIX), also known as the fear gauge, jumped to more than 28, its highest level since Feb 12, 2018. This suggests that market fears have started to set in. This fear gauge tends to outperform when markets are falling or fear levels over the future are high. The global equity index dropped to a one-year low while the three major U.
VDE DMRL SCHV XOP AIRR ITB FTLB

 
ETFs That Tend To Win & Lose When Rates Rise

2018-10-10 zacks
Treasury yields have been surging lately on the back of strong economic data and hawkish Fed comments. The 10-year yield jumped above 3.25% for first time since 2011, sparking fears of inflationary pressure, which would increase the cost of products and dampen consumer spending. This in turn would hurt economic growth, making investors cautious about the longevity of the longest bull run in U.S. equities (read: Yields Are Soaring: Here's How to Short Treasury With ETFs).
USO XOP ITB KRE UNG GDXJ

 
ETFs That Tend To Win & Lose When Rates Rises

2018-10-10 zacks
Treasury yields have been surging lately on the back of strong economic data and hawkish Fed comments. The 10-year yield jumped above 3.25% for first time since 2011, sparking fears of inflationary pressure, which would increase the cost of products and dampen consumer spending. This in turn would hurt economic growth, making investors cautious about the longevity of the longest bull run in U.S. equities (read: Yields Are Soaring: Here's How to Short Treasury With ETFs).
USO XOP ITB KRE UNG GDXJ

5
A Sober Look At Housing In The Middle Of All The Chaos

2018-10-05 seekingalpha
While the stock market continues to hit new all-time highs, the volatility in interest rate explodes, and political theatrics consume most media outlets, the housing market has had a very stealth slowdown that should start to be a cause for concern. The housing market has gone from a "yellow light" to a "red light" based on the recent data, and the housing-related equities support that view with the iShares U.
LOW HD KBH TOL DHI LEN ITB

 
Time to Buy Beaten-Down Homebuilder ETFs?

2018-09-27 zacks
The U.S. housing market has started to show signs of respite given the slew of upbeat data. After two months of consecutive decline, new home sales rebounded in August, climbing 3.5% to a seasonally adjusted annual rate of 629,000. A report last week showed housing starts came in above expectations, rising 9.2% in August — the highest increase in seven months. Additionally, existing home sales also remained stable last month after four straight months of decline.
XHB ITB

1
Homebuilder ETFs in Focus as Starts Jump, Permits Fall

2018-09-20 zacks - 1
The struggling homebuilding industry heaved a sigh of relief after housing starts data for August came in above expectations and saw the biggest increase in seven months. U.S. housing starts climbed 9.2% to a seasonally adjusted annual rate of 1.28 million units. The solid data came after a decline of 0.3% in July and 11.4% in June. The uptick in construction activity was driven by a solid 29.3% surge in apartment construction and a modest rise of 1.
XHB ITB

7
Homebuilder Confidence Stays Steady in September: 5 Top Picks

2018-09-19 zacks - 1
The confidence level among the nation's homebuilders for newly-built, single-family homes remained unchanged in September from the prior month on the National Association of Home Builders/Wells Fargo Housing Market Index (HMI). Although builders remain perturbed with rising costs and continued shortage of skilled labor, a growing economy and rising income along with increasing household formations raise optimism.
CCS KBH DHI PHM LEN BZH ITB BZMD

 
Renting Preferred Over Buying: Industrial ETFs in Focus

2018-09-12 zacks
Recent times have seen a shift in U.S. housing market sentiments as renting is being preferred over buying. As per research conducted by Florida Atlantic University and Florida International University faculty, in 16 out of 23 major metropolitan cities, renting has outperformed ownership. These cities include Atlanta, Dallas, Denver, Houston, Los Angeles, Miami, San Francisco and Seattle. It is still better to buy than rent in much of the Midwest and Northeast, with Chicago and Cleveland showing the best ownership scores (see all Industrials ETFs here).
XHB ITB

 
Home Prices Have Officially Started To Fall, Here's What It Means For Your Portfolio

2018-09-05 seekingalpha
I warned throughout the summer that the West Coast housing market is no longer supported by the underlying fundamentals.
ITB

1
Bull of the Day: DR Horton Inc.

2018-08-22 zacks
DR Horton (DHI - Free Report) is America’s biggest homebuilder by volume and has held that position for the last 16 years. They operate in 26 states across the country and now build about 50,000 new homes per year in a wide range of prices from $100,000 to over $1,000,000. Homebuilding stocks have been sluggish in 2018, as fears of increased costs - as a result of lumber tariffs - and higher interest rates have had investors concerned about both margin and demand for new homes.
MLNX HEAR ITB

 
Has The Housing Market Peaked?

2018-08-03 seekingalpha
Real estate investors are increasingly asking whether the U.S. housing market has hit a peak. A series of recent sales and activity data have put some teeth behind this question for the first time in recent memory. As we'll see in this commentary, however, while a further slowdown in home buying activity in coming months is possible the likelihood is that the 7-year-old real estate bull market will live on.
IYR ITB

7
Housing ETFs Seesaw Between Poor Sales Data & Solid Earnings

2018-07-30 zacks
Home sales data was downbeat in June while earnings from one of the key companies, D.R. Horton (DHI - Free Report) came in upbeat on Jul 26, helping housing ETFs stay afloat. Let’s delve a little deeper into the picture.
XHB ALGN KBH MTH DHI NVR ITB

 
Homebuilder ETFs in Focus on Solid New Home Sales Data

2018-06-26 zacks
The housing market has perked up with the start of summer thanks to soaring demand for homes. This is especially true as new home sales jumped to the highest level in May since November 2017. Sales of new homes in the United States rose 6.7% to a seasonally adjusted annual rate of 689,000 in May. The robust growth was driven by an inventory crunch for previously owned houses. The median sales price in May was 3.
XHB ITB

 
Housing Starts Scale 11-Year High: ETFs in Focus

2018-06-20 zacks
Though homebuilders are struggling with higher lumber prices as well as labor and land shortages, an upbeat housing starts report was a silver lining in the space. U.S. housing starts climbed 5% in May to a seasonally adjusted annual rate of 1.35 million homes, representing the highest level since July 2007. The uptick in construction activity was driven by acceleration in both single-family and multi-family home construction that rose 3.
XHB ITB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ITB / iShares U.S. Home Construction ETF on message board site Silicon Investor.

FITBIT - tell us about your device FITBIT - tell us about your device FITBIT - tell us about your device Andrew Breitbartu0027s Work Continues Andrew Breitbartu0027s Work Continues Andrew Breitbartu0027s Work Continues
FITB (Fifth Third Bancorp) FITB (Fifth Third Bancorp) FITB (Fifth Third Bancorp) Hometown Auto (HCAR) - an internet/web play - profitbl co. Hometown Auto (HCAR) - an internet/web play - profitbl co. Hometown Auto (HCAR) - an internet/web play - profitbl co.
Pitbull Investing Strategies Pitbull Investing Strategies Pitbull Investing Strategies
CUSIP: 464288752